James Niedel
Director/Board Member bij Tioga Pharmaceuticals, Inc.
Profiel
James Niedel is a Venture Partner and focuses on our biopharmaceuticals efforts.
He was one of the founders of New Leaf in 2005, having moved with the healthcare team from Sprout, where he had been a venture partner since 2002.
Prior to joining the venture industry, Jim was Chief Science and Technology Officer for GlaxoSmithKline and from 1995 to 2001 he was a member of the board of directors of Glaxo Wellcome plc with responsibility for Global Research and Development, Information Technology and Product Strategy.
From 1988 to 1995, he was VP Research and SVP R&D for the US subsidiary of Glaxo.
Before joining the pharmaceutical industry, Jim was Professor of Medicine and Chief of the division of Clinical Pharmacology at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Oncology fellowship.
He received M.D.
and Ph.D.
(Biochemistry) degrees from the University of Miami, was selected a Searle Scholar, and is a Fellow of the Royal College of Physicians (London).
Jim also serves on the Scientific Advisory Board of the Tri-Institutional Therapeutics Discovery Institute (Tri-TDI) formed by Weill Cornell Medical College , the Rockefeller University and Memorial Sloan-Kettering Cancer Center, in partnership with Takeda Pharmaceutical Company.
Actieve functies van James Niedel
| Bedrijven | Functie | Begin |
|---|---|---|
Tioga Pharmaceuticals, Inc.
 Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA. | Director/Board Member | - |
Eerdere bekende functies van James Niedel
| Bedrijven | Functie | Einde |
|---|---|---|
| CHIMERIX, INC. | Chairman | 20-02-2013 |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Director/Board Member | 19-12-2011 |
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Chairman | 29-12-2006 |
Sprout Group
 Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | Private Equity Investor | 31-12-2004 |
| Glaxo Wellcome Plc | Director/Board Member | 30-12-2001 |
Opleiding van James Niedel
| University of Miami | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| Bedrijven in privébezit | 11 |
|---|---|
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
| Glaxo Wellcome Plc | Health Technology |
Oriel Therapeutics, Inc.
 Oriel Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oriel Therapeutics, Inc. develops inhaled drug delivery systems for respiratory diseases and diagnostics. It is a respiratory drug delivery and development company serving the pharmaceutical, biotechnology and diagnostic industries in the development and commercialization of innovative pre-metered unit and multi-dose dry powder delivery systems for medicines for asthma and chronic obstructive pulmonary disease. The company was founded by Paul J. Atkins, Timothy M. Crowder, Richard Fuller and Anthony J. Hickey in 2002 and is headquartered in Durham, NC. | Health Technology |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
Sopherion Therapeutics LLC
 Sopherion Therapeutics LLC BiotechnologyHealth Technology Sopherion Therapeutics LLC develops and commercializes anti-cancer therapies. The company was founded by Ronald H. Goldfarb and Salvatore Forenza in 2002 and is headquartered in Princeton, NJ. | Health Technology |
Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA. | Health Technology |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | Finance |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
New Leaf Venture Partners LLC
 New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group. | Finance |
Pearl Therapeutics, Inc.
 Pearl Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pearl Therapeutics, Inc. develops therapies for the treatment of chronic respiratory diseases. It offers respiratory product development, high quality therapies for COPD, Asthma and treatment and prevention of chronic respiratory diseases and asthma. The company was founded in 2006 by Sarvajna Dwivedi and is headquartered in Redwood City, CA. | Health Technology |
GlaxoSmithKline Pharmaceuticals SA (Belgium)
 GlaxoSmithKline Pharmaceuticals SA (Belgium) Pharmaceuticals: MajorHealth Technology GlaxoSmithKline Pharmaceuticals SA develops and manufactures pharmaceuticals and vaccines. The company is headquartered in Wavre, Belgium. | Health Technology |
